fluoxetine has been researched along with Tremor in 17 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 9.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The cardinal motor symptoms of Parkinson's disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ)." | 7.81 | Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. ( Contreras-Mora, HM; Correa, M; Milligan, MN; Podurgiel, SJ; Purcell, LJ; Salamone, JD; Yohn, SE, 2015) |
| "4 years, who developed tremor after receiving fluoxetine at a mean dose of 25." | 7.71 | Fluoxetine-induced tremor: clinical features in 21 patients. ( Serrano-Dueñas, M, 2002) |
| "Clonidine exhibited a dose-dependent protection against harmine-induced tremors in mice." | 7.67 | Modification by clonidine of harmine-induced tremors in mice: involvement of serotoninergic system. ( Garg, SK; Kulkarni, SK; Shukla, VK, 1986) |
| " For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to ." | 5.07 | Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 5.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The cardinal motor symptoms of Parkinson's disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ)." | 3.81 | Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. ( Contreras-Mora, HM; Correa, M; Milligan, MN; Podurgiel, SJ; Purcell, LJ; Salamone, JD; Yohn, SE, 2015) |
| "4 years, who developed tremor after receiving fluoxetine at a mean dose of 25." | 3.71 | Fluoxetine-induced tremor: clinical features in 21 patients. ( Serrano-Dueñas, M, 2002) |
| "Clonidine exhibited a dose-dependent protection against harmine-induced tremors in mice." | 3.67 | Modification by clonidine of harmine-induced tremors in mice: involvement of serotoninergic system. ( Garg, SK; Kulkarni, SK; Shukla, VK, 1986) |
| "To determine whether SSRIs impact disease progression, fluoxetine (Prozac, 5 or 10 mg/kg) was administered to mutant superoxide dismutase 1 (SOD1) mice during one of three age ranges: neonatal [postnatal day (P)5-11], adult presymptomatic (P30 to end stage), and adult symptomatic (P70 to end stage)." | 1.40 | Effect of fluoxetine on disease progression in a mouse model of ALS. ( Heckman, CJ; Kajtaz, E; Kocevar, EJ; Koschnitzky, JE; Lukas, TJ; Mayers, WF; Quinlan, KA; Siddique, T, 2014) |
| "Because of a depressive syndrome, a 39-year-old patient received 20 mg fluoxetine per day." | 1.29 | [A case of rare side effects of certain antidepressive drugs]. ( Haenel, T; Stöckli, HR; Truog, P, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 9 (52.94) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koschnitzky, JE | 1 |
| Quinlan, KA | 1 |
| Lukas, TJ | 1 |
| Kajtaz, E | 1 |
| Kocevar, EJ | 1 |
| Mayers, WF | 1 |
| Siddique, T | 1 |
| Heckman, CJ | 1 |
| Podurgiel, SJ | 1 |
| Milligan, MN | 1 |
| Yohn, SE | 1 |
| Purcell, LJ | 1 |
| Contreras-Mora, HM | 1 |
| Correa, M | 1 |
| Salamone, JD | 1 |
| Rittmannsberger, H | 1 |
| Werl, R | 1 |
| Serrano-Dueñas, M | 1 |
| D'Souza, DC | 1 |
| Bennett, A | 1 |
| Abi-Dargham, A | 1 |
| Krystal, JH | 1 |
| Haenel, T | 1 |
| Stöckli, HR | 1 |
| Truog, P | 1 |
| Fernández López, MI | 1 |
| Sánchez Esteban, J | 1 |
| Jímenez Belló, J | 1 |
| Meseguer Zaragoza, A | 1 |
| Takeuchi, H | 1 |
| Yatsugi, S | 1 |
| Hatanaka, K | 1 |
| Nakato, K | 1 |
| Hattori, H | 1 |
| Sonoda, R | 1 |
| Koshiya, K | 1 |
| Fujii, M | 1 |
| Yamaguchi, T | 1 |
| Anand, KS | 1 |
| Prasad, A | 1 |
| Pradhan, SC | 1 |
| Biswas, A | 1 |
| Darko, W | 1 |
| Guharoy, R | 1 |
| Rose, F | 1 |
| Lehman, D | 1 |
| Pappas, V | 1 |
| Austin, LS | 1 |
| Zealberg, JJ | 1 |
| Lydiard, RB | 1 |
| Beasley, CM | 1 |
| Dornseif, BE | 1 |
| Pultz, JA | 1 |
| Bosomworth, JC | 1 |
| Sayler, ME | 1 |
| Feighner, JP | 1 |
| Boyer, WF | 1 |
| Tyler, DL | 1 |
| Neborsky, RJ | 1 |
| Hansen, TE | 1 |
| Dieter, K | 1 |
| Keepers, GA | 1 |
| Levine, S | 1 |
| Deo, R | 1 |
| Mahadevan, K | 1 |
| Shukla, VK | 1 |
| Garg, SK | 1 |
| Kulkarni, SK | 1 |
| Chouinard, G | 1 |
3 trials available for fluoxetine and Tremor
| Article | Year |
|---|---|
Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Depressive Disorder; Dizziness; Double-Bli | 1991 |
A comparative trial of a new antidepressant, fluoxetine.
Topics: Adult; Aged; Body Weight; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female | 1987 |
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Amitriptyline; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Di | 1985 |
14 other studies available for fluoxetine and Tremor
| Article | Year |
|---|---|
Effect of fluoxetine on disease progression in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; | 2014 |
Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Rela | 2015 |
Does aripiprazole protect from serotonin syndrome?
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Borderline Pers | 2012 |
Fluoxetine-induced tremor: clinical features in 21 patients.
Topics: Adult; Aged; Cohort Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Olivary Nucleus; Red Nuc | 2002 |
Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Male; Middle Ag | 1994 |
[A case of rare side effects of certain antidepressive drugs].
Topics: Adult; Antidepressive Agents; Clomipramine; Depressive Disorder; Diagnosis, Differential; Drug Thera | 1995 |
[Suggestive episodes of hypoglycemia related to fluoxetine].
Topics: Adult; Diabetes Mellitus, Type 2; Diagnosis, Differential; Dizziness; Female; Fluoxetine; Humans; Hy | 1996 |
Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity.
Topics: Animals; Citalopram; Fluoxetine; Learning; Mice; Mice, Inbred ICR; Morpholines; Olfactory Bulb; Oxot | 1997 |
Fluoxetine-induced tremors.
Topics: Adult; Antidepressive Agents, Second-Generation; Diagnosis, Differential; Female; Fluoxetine; Humans | 1999 |
Myoclonus secondary to the concurrent use of trazodone and fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Drug Synergism; Fluoxetine; HIV Infecti | 2001 |
Three cases of pharmacotherapy of obsessive-compulsive disorder in the elderly.
Topics: Age Factors; Aged; Clomipramine; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Tr | 1991 |
Adverse consequences of fluoxetine-MAOI combination therapy.
Topics: Adult; Akathisia, Drug-Induced; Confusion; Depressive Disorder; Drug Interactions; Drug Therapy, Com | 1990 |
Interaction of fluoxetine and pentazocine.
Topics: Adult; Anxiety; Ataxia; Drug Interactions; Fluoxetine; Humans; Hypertension; Male; Nausea; Paresthes | 1990 |
Modification by clonidine of harmine-induced tremors in mice: involvement of serotoninergic system.
Topics: Alkaloids; Animals; Clonidine; Cyproheptadine; Fluoxetine; Harmine; Male; Mice; Quipazine; Serotonin | 1986 |